Predictive, Preventive & Personalized Medicine and Molecular Diagnostics

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, Suchkov maintained his Doctor Degree at the National Institute of Immunology, Russia.From 1989 through 1995, Dr Suchkov was being a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004 - a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, Dr Suchkov was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.At present, is Prof Sergey Suchkov, MD, PhD , I.M.Sechenov First Moscow State Medical University, Moscow Engineering Physical Institute (MIFI)

Personalized Medicine and Transnational Medicine

Silvia Binder, ND PhD is the CEO of the Ondamed Companies and the Founder of The Binder Institute for Personalized Medicine in Southern Germany where she helps chronically ill patients from around the world. She was born in Germany, grew up in Vienna, Austria, and lived in New York for 20 years. Dr. Binder lectures around the globe, offers Courses on Bio-IT Integrative Personalized Medicine, is faculty of the American Academy for Anti-Aging Medicine and serves on several medical Advisory Boards in North America. She is the author of various scientific papers and the book “ONDAMED A story of love, healing, and medical revolution

Personalized Biological Therapies

Anatoly V Skalny has completed his PhD from All-Union Centre for Narcology, Moscow, Russia. He is the Vice-President of Trace Element Institute for UNESCO, the Chairman of Russian Society of Trace Elements in Medicine and the Vice-President of the Federation of European Societies on Trace Elements and Minerals (FESTEM). He has published more than 200 journal articles, abstracts and book chapters in English. He is a Member of Editorial Board of Journal of Trace Elements in Medicine and Biology.

Dr Fratazzi devised the concept of SCIO and founded the first SCIO –BBCR Consulting in 2009, with the objective of actively contributing to innovation in the clinical process. She acts as a consultant to drug and device companies, and investors. She is a renowned Immunologist; contributed to the registration of 4 drugs. Recipient of 2013, 2014 and 2015 Best Pharmaceutical Consultant, Member of Advisory Board and Board of Directors; Invited speakers and chairman at international conferences. Dr Fratazzi received her early training at the Johns Hopkins University and Harvard University in the USA, and at Imperial College in London

Bachelor and Master in Clinical and Health Psychology at Aveiro University (Portugal) and internship in Coimbra Hospital University Centre (e.g., Intervention in Sleep Disorders and Pain Disorders). Later, worked as a psychologist and neuropsychologist. Also performed a research project in Biofeedback/Neurofeedback by the Foundation for Science and Technology (FCT). Concomitantly, made several national and international communications in various Congress as Guest Speaker in the field of Neuroscience. Editor in Chief and Founder of the International Journal of Psychology and Neuroscience and Editor in several Scientific Journals and Author of various articles in peer review journals. At the moment, is a Ph.D. student in Neuroscience at the Faculty of Medicine, University of Salamanca – Neurosciences Institute of Castilla y León.

Research interests: Experimental Psychology, Neuropsychology and Biological Rhythms, particularly in: Assessment and Neuropsychological Rehabilitation, Drug Abuse and Addiction, Behavioural Neuroscience, Behavioural Management, Biofeedback/Neurofeedback, Sleep Disorders, Pain Disorders.

Nadiia Kryzhanovska has completed PhD in 2000 year (scientific and postdoctoral studies from Medical state academy, Hospital of Dnipro). In 2013 year has founded the Personal Medicine Clinic, Ukraine, concentrated on creation of the personalized preventive programs in cardiology, general medicine, oncology, gynecology, urology, neurology as well as rehabilitation. The CEO of Personal Medicine Clinic at present time, the premier scientific consultant of ArtWorld and DNAforLife (Dubai) and ArtMedCy (Cyprus). Has published more than 40 papers in reputed journals and has been serving as editorial board member of repute. International speaker of WOSIAM (AMWC, AMEC), ESC, EACPR, IFM membership

Anatoly V Skalny has completed his PhD from All-Union Centre for Narcology, Moscow, Russia. He is the Vice-President of Trace Element Institute for UNESCO, the Chairman of Russian Society of Trace Elements in Medicine and the Vice-President of the Federation of European Societies on Trace Elements and Minerals (FESTEM). He has published more than 200 journal articles, abstracts and book chapters in English. He is a Member of Editorial Board of Journal of Trace Elements in Medicine and Biology.

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, Suchkov maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1989 through 1995, Dr Suchkov was being a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004 - a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, Dr Suchkov was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr Sergey Suchkov, MD, PhD, is: ● Professor, Chair, Dept for Personalized and Translational Medicine, I.M.Sechenov First Moscow State Medical University and Dept of Clinical Immunology, A.I.Evdokimov Moscow State Medical and Dental University; ● Secretary General, United Cultural Convention (UCC), Cambridge, UK. Dr Suchkov is an author of more than 500 publications including 10 patents and more than 10 monographs, handbooks and textbooks published in Russia and USA. Dr Suchkov is a member of the: ● New York Academy of Sciences, USA ● American Chemical Society (ACS), USA; ● American Heart Association (AHA), USA; ● European Association for Medical Education (AMEE), Dundee, UK; ● EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ● ARVO (American Association for Research in Vision and Ophthalmology)

Dr Fratazzi devised the concept of SCIO and founded the first SCIO –BBCR Consulting in 2009, with the objective of actively contributing to innovation in the clinical process. She acts as a consultant to drug and device companies, and investors. She is a renowned Immunologist; contributed to the registration of 4 drugs. Recipient of 2013, 2014 and 2015 Best Pharmaceutical Consultant, Member of Advisory Board and Board of Directors; Invited speakers and chairman at international conferences. Dr Fratazzi received her early training at the Johns Hopkins University and Harvard University in the USA, and at Imperial College in London

Silvia Binder, ND PhD is the CEO of the Ondamed Companies and the Founder of The Binder Institute for Personalized Medicine in Southern Germany where she helps chronically ill patients from around the world. She was born in Germany, grew up in Vienna, Austria, and lived in New York for 20 years. Dr. Binder lectures around the globe, offers Courses on Bio-IT Integrative Personalized Medicine, is faculty of the American Academy for Anti-Aging Medicine and serves on several medical Advisory Boards in North America. She is the author of various scientific papers and the book “ONDAMED A story of love, healing, and medical revolution”

Personalized Biological Therapies

Massimo Cecaro was born in Macerata, Italy, in 1980. After completing the high school in humanistic studies, he moved to the University of Camerino, where he got a Master Degree in Veterinary Medicine and in University of Teramo he successfully got the Specialization. Since the age of 14, he has worked as radio speaker, tv presenter and reporter for a wide range of artistic and scientific events. At the age of 24 he obtained a qualification to practice as a Journalist and in 2007 he was admitted to the National Association of Medical Press (ASMI), where he currently hold the position of National Councilor. He is Resident Member of MJA Medical Journalists Association (London). He has been lecturer of Communication in Medical Sciences in many Universities. He has been an invited speaker at international events in the field of Public Health and Safety. He has been author of several scientific works in public health. He is also director of a prestigious Educational Centre for work safety and public health. He is actively involved in international projects to improve the role of mass-media in medical sciences, and awarded in Philadelphia, with international special recognition and also member of EFSA\s Expert Database (European Food Safety Authority).

Personalized Medicine

Jon Burroughs, MD, MBA, FACHE, FAAPL is President and CEO of The Burroughs Healthcare Consulting Network, Inc. and works with some of the nation’s top healthcare consulting organizations to provide ‘best practice’ solutions and training to healthcare organizations throughout the country in the areas of governance, physician–hospital alignment strategies, as well as ways in which physicians and management can work together in new ways to solve quality, safety, operational, and financial challenges through the creation of population health programs and clinically integrated networks.

Dr. Burroughs serves on the national faculty of the American College of Healthcare Executives and the American Association for Physician Leadership, where he has been consistently rated as one of their top speakers and educators. He is the author of “Redesign the Medical Staff Model-A Collaborative Approach (published by Health Administration Press, January, 2015 which was honored with the 2016 James A. Hamilton Award for outstanding healthcare management book.

Carlos Camps, PhD extraordinary award in 1983, won in 1989 Specialist Certification in Medical Oncology at the European Medical Oncology Society (London) and the title of Master in Molecular Biology from the Francisco de Vitoria University in Madrid. In addition, it also has the title of Specialist and Master in Management of Health Systems and Hospitals at the Polytechnic University of Valencia. He was president of the ECO Foundation (Excellence and Quality in Oncology) until last year and vice president of SAISE Committee of the Ministry of Health of the Generalitat Valenciana. He is currently evaluating the Cancer Institute of France, the Italian Society of Oncology, of Andalusia and Madrid Carlos III Institute. Dr. Camps has organized more than 120 conferences and scientific meetings, and participate in numerous research projects linked to lung cancer.

research focuses on the Cancer Research.

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, Cell Science, Trace Elements, Biology, Biomedical Laboratory

Irina V. Zhegalova is a member of Young Research Team under the aegis of EPMA (Brussels, EU) and ISPM (Tokyo, Japan). She is a participant and speaker at international congresses in predictive preventive and personalized medicine worldwide. Irina is an author of several articles in application of bioinformatics in personalized medicine. Nowadays Irina activity performs a research in genomics and clinical bioinformatics, interested in e-Health.

Genomics and clinical bioinformatics, interested in e-Health.

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Anatoly Victorovich Skalny was born on the 12th of April, 1962 in Ivano-Frankovsk-City (Ukrain). Graduated school in Olyka village of Volynskaya oblast and medical faculty of Ivano-Frankovsk Medicine State Institute (1985) with honours. Began to carry aout scientific researches from 1979 in a student scientific society under the leadership of professor G.A. Babenko, a leading specialist in medicine elementology in Soviet Union. Ph.D. in Medicine (from 1990). Member of Council on trace elements in agriculture, biology and medicine in AS USSR and RAS (from 1987), Executive Committee of Moscow department of physicians-assistants' Society (from 1989), Boards in ecology and natural recources, science, culture and public health Political Consulting Council under the President of Russian Federation (from 1997), Member of advisory committee in ecology at Moscow City Parliament, co-founder of public movement "Healthy City - health of moscovites" (from 1998). In 1985–1991 worked as a research assistant, Junior Researcher and Researcher in department of restoration treatment of children with cerebral paralysis of Research Institute of common and justice psychiatry by V.P.Serbsky of HM USSR, department of alcoholism genetics in State Scientific Center of narcology of HM USSR. In 1988 he founded scientific-medical center "Element" that is the base to carry out researches of biosubstrates elemental content for medicine purposes during 11 years (for population, health and sanitary-hygienic organizations), scientific institutes such as Research Institute of pediatrics of RAMS, Center for perinatology, obstetrics and gynaecology of HM RF, Navy Institute of Hygiene of HM RF, colleges of medicine of Moscow, Ivanovo, Irkutsk, N.Novgorod and other cities. Center for Biotic Medicine, - autonomous non-profit organization (CBM), - was founded by A.V.Skalny in 1995 that is the unique scientific-methodical Center for problems of applied medicine elementology in RF and UIS. On the 19 of January, 2001 "Russian Society of Medicine Elementology" (RUSTEM) was founded to provide the strongest evolution of trace elements paradigm. During the period from 1982 about 200 scientific articles and thesis' were published by A.V.Skalny in special issues in Russia and abroad as well as manuals and mini-monographs in problems of practical medicine elementology. A.V. Skalny with co-authors registered 3 certificates of authorship and 3 patents of RF and Ukrain in the branch of producing new biologically active compounds of trace elements (Se, Zn) to treat and make prophylaxis of human diseases, methods of treatments of zinc deficiency states, alcohol coma and schysophrenia. To date new line in medicine and ecology, - medicine elementology, - is established by A.V. Skalny in Russia and UIS and developed successfully that studies peculiarities of human organism elemental composition in different functional states and disorders and the ways to increase organism adaptative functions with the help of trace elements metabolism correction. In SMC "Element" and CBM more than 20 Ph.D.'s and 5 D.Sc.' in medicine and biology were trained who develop different applied aspects of medicine elementology in branches of perinatology, endocrinology, urology, nephrology, labour medicine, nutrition hygiene, narcology in leaders clinics of Russia, Ukrain, Kazakhstan, Uzbekistan. In 1998-1999 production of new generation of effective major and trace elements' preparations (compounds with aspartic, spirulina) was organized under the methodic management of organizations headed by A.V. Skalny that awoke interest of specialists and consumers home and abroad. On April, 2003 A.V. Skalny opened the first chair of nutritiology and bioelementology in Russia and became its leader. From September, 2003 Bioelementology Institute, the first in the world, being founded by A.V. Skalny under support of Orenburg State University rectorate and RUSTEM, began its activity.

Internal Medicine (General Medicine)

Farid Menaa is an inter- and multi-disciplinar professional (director, professor, researcher and entrepreneur) with increasing international recognition. His strong background is mainly related to medecine, biology, pharmaceutical sciences, biochemistry, biophysics and genetics. Dr. Menaa has studied and worked for/with several reputed institutions worldwide, including Sorbonne (Paris, France), CNRS (France), INSERM (France), CEA (Ministry of Defence, France), SKCC/sanford-Burnham Medical Research Institute (USA), Schools of Medecine of Paris (France), Wuerzburg (Germany) and Campinas (Unicamp, Brazil). Among other responsibilities he carried out, Dr. Menaa has been, for several years, the R&D director of Fluorotronics, Inc. San Diego, CA, USA, a premier company specialized in fluorine chemistry and nanotechnology. Dr. Menaa was also a principal investigator in projects related to Oncology, Dermatology, Stem Cells, Genetics and Hematology. Dr. Menaa is currently an international consulting expert in healthcare and biosystems for a number of organizations and serves as an editorial board member for a large number of esteemed journals in medecine, sciences and business. Dr. Menaa holds dozen of peer-reviewed manuscripts and is a respected member of prestigious scientific/medical organizations and meetings where he is often invited as a chairman.

Medicine; Genetics; Fluorine Chemistry; Nanotechnology; Biophysics; Biochemistry

Professor Mittra obtained his medical degree from University of Delhi and is a Fellow of the Royal College of Surgeons of England and holds a PhD degree from University of London. He did his post-doctoral training with Dr Renato Dulbecco, Nobel Laureate, at the Imperial Cancer Research Laboratories in London. Professor Mittra is a multi-faceted personality. He is a breast cancer surgeon while at the same time being deeply involved in public health and basic research in cancer. Professor Mittra’s current research interests lie in the area of biology of extracellular nucleic acids and their role in ageing, inflammation, degenerative disorders and initiation and metastatis of cancer

Public health and basic research in cancer

Adrian L Lerena is the Director of the Clinical Research Center in the University Hospital Infanta Cristina en Badajoz Spain. He is also Professor of Pharmacology and Clinical Pharmacology in two Medical Schools in the University of Extremadura Spain and part time in the University of Beira Interior, Portugal. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics of antidepressant and antipsychotic drugs. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 PhD thesis

Pharmacology, Personalized Medicine

Acupuncture therapist Serving in holy city ,amritsar ,india , from last 16 years at guru kirpa acupuncture and holistic care center . Spent almost 7 years in the professional study of acupuncture at ludhiana ,kolkata ,coimbatore and canada. Attended 15 national and international acupuncture conferences , in punjab , tamil nadu ,delhi , kolkata , edmonton ( canada ) , lahore ( pakistan ), philadelphia ( u.s.a. ), china . And presented acupuncture papers in 9 conferences out of them . 1.Vice chairman – the alliance of research & development traditional medicines , fudan university ,china. 2.Vice president- acupuncture science association , punjab unit , india . 3.Member - tamilnadu acupuncture council , tamil nadu , india . 4.Member - pakistan acupuncture council , pakistan

Acupuncture therapist

Andreas Scherer is the Project Director for Institute for Molecular Medicine Finland (FIMM)and previously he was a founder and CEO of Spheromics, a company focused on consultancy in biomarker development, as well as analysis and interpretation of complex biomedical datasets. Dr Scherer is a molecular and computational biologist with long experience in gene expression profiling and biomarker development and qualification. Before founding Spheromics in 2007, Dr Scherer worked in various positions for Novartis in Basel, Switzerland. In 2011 he accepted the position Bioinformatics Manager at the Australian Genome Research Facility (AGRF) in Melbourne, AU, from where he returned to Finland in 2013. Dr Scherer is author and co-author of a number of articles in peer-reviewed journals, book chapters, and editor of a book about unwanted variation in microarray datasets. He is advisory board member of the journal “OA Bioinformatics”.

Bioethics, Genomics, Biomarkers

Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Howard Moskowitz, Harvard PhD in experimental psychology (1969) is founding partner and chief scientific officer of Mind Genomics Advisors. He has published extensively in many fields, using the science of Mind Genomics, which he invented more than 30 years ago. After a distinguished dual career in science and business, he changed course, creating an institute to help younger professionals as well as students and business, benefit from the application of Mind Genomics to practical problems in society, including commerce, health, education, and socal issues. Along with hundreds of scientific papers, he has written/edited 27 published books, with an additional 15 books finished but not yet published. His ‘oeuvre’ of work using Mind Genomics is available for download to interested parties at https://www.dropbox.com/sh/vlyiqp6p5eom0m1/AAC1WRPuHOGpax6TLq-md824a?dl=0

Genomics

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services.

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Sergey Zhuplatov is a Medical Director of the Metabolic Strategy and Development of AstraZeneca LP. Fort Washington, PA. He was graduated as MD at the Izhevsk State Medical Academy in Russia before finishing his fellowship in Internal Medicine/Endocrinology at Moscow Academy of Post diploma Education and Moscow Medical Institute of Transplantology in 1986. He accepted tenure and leading clinical consultant position in Endocrinology/Cardiology clinic at his Alma Mater ISMA. At this time, he started his Ph.D. dissertation in Cardiology with prevention of progressive CV events in Diabetes Mellitus Patients as the main topic, which was perfectly defended at Ural State Medical Academy on 1991. Dr. Zhuplatov has been working as an Assistant Professor and practicing physician till his emigration to the USA in 2002 as an exceptional ability person visa waiver. Before that he worked 2 years as a Medical Scientific Consultant for Merck S&D Co., and also as a Chief Medical Officer in Private Medical Clinic for 2 years. He published different works in Internal Medicine, Lipidology, Endocrinology, and Cardiology. He continued his scientific work in University of Utah Medical School till his merge to Pharmaceutical Industry in 2008. Since then he is working in Cardio/Metabolic area of Medical Affairs and Clinical Development of Bristol-Meyers Squibb and AstraZeneca Co. He currently resides in Bucks County PA with his wife Irina, Industrial Psychology Ph.D. They both like fine arts, travel, and reading. His two sons are graduate students in Economy and Medicine.

Diabetology,Lipids,Ischemic Heart Disease, Microcirculation,Echocardiography,Obesity.

Luigi Maselli received the Distinguished Doctor Award at San Raffaele University of Rome in honor of his significant contribution to Lifestyle Medicine in Italy. He is a neuroimmunologist with a PhD in Neurosciences and works as a Research Fellow at Sapienza University of Rome – School of Medicine and Dentistry and as a Visiting Fellow at Gabriele d’Annunzio University of Chieti-Pescara – School of Health Sciences. Dr. Maselli is the founding President of the Italian Lifestyle Medicine Association (ILMA). He is active in patient care, research, speaking, teaching and writing, and wrote the first Italian book on Lifestyle Medicine. After establishing his connection with the Institute of Lifestyle Medicine at Harvard Medical School, where he fell in love with Lifestyle Medicine, he established Lifestyle Medicine programs in several Italian universities. His overwhelming enthusiasm for life and propensity for helping others reflect the values that make Lifestyle Medicine unique- for the treatment and prevention of lifestyle-related chronic diseases.

Internal Medicine

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, cell science, Trace elemts, biology, Biomedical Laboratory.

Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Personalized Medicine, Clinical research

Chakrabarty is currently a Distinguished University Professor in the Department of Microbiology and Immunology in the University of Illinois at Chicago College of Medicine. Apart from being an eminent scientist, Ananda Chakrabarty has been an advisor to judges, governments, and the UN.As one of the founding members of a United Nations Industrial Development Organization committee that proposed the establishment of the International Centre for Genetic Engineering and Biotechnology, he has been a member of its Council of Scientific Advisors ever since.He has served the U.S. government as a member of NIH Study Sections, a member of the Board on Biology of the National Academy of Science, and the Committee on Biotechnology of the National Research Council He has also served the Stockholm Environment Institute of Sweden. He has been on the scientific advisory boards of many academic institutions such as the Michigan Biotechnology Institute, the Montana State University Center for Biofilm Engineering, the Center for Microbial Ecology at the Michigan State University, and the Canadian Bacterial Diseases Network based in Calgary, Canada. Dr. Chakrabarty has also served as a member of the NATO Industrial Advisory Group based in Brussels, Belgium. He is a member of the board of directors of Einstein Institute for Science, Health and the Courts, where he participates in judicial education. More recently, he has been involved in international judicial work, serving as a Scientific Advisor for meetings in Hawaii and Ottawa, Canada, organized by the Supreme Court of Canada.

Cell Biology, Microbiology, Oncology,Biotechnology, Cancer cells

Hu is currently Senior Vice President and Head of Consulting in the US for the Pharmaceutical and Diagnostics industries at GlobalData Inc., a publicly listed global healthcare business intelligence and management consulting firm with a headquarter in London, UK. Earlier, aside from being the founding President of BioStrat Advisory LLC, for years he was the Managing Partner and Head of Bionest USA, both life science industry strategy consulting firms in the US. An early participant of the Human Genome Project and later involved in the International HapMap Project, Dr. Hu is now a recognized thought leader in the field of personalized / precision medicine (PM) business strategy, advising global pharmaceutical and diagnostics companies on how best to develop and commercialize personalized medicine drug and / or molecular diagnostics, and build internal business processes & capabilities for PM products. He currently serves on the Editorial Board of the peer-reviewed journal Personalized Medicine, in addition to several PM related industry consortia/committees. For example, he was the only representative from the management consulting industry invited to the US FDA Personalized Medicine Initiative, and co-organized / co-chaired a two-day conference / workshop on Personalized Medicine Strategic Decision Making onsite at the US FDA campus. He was also a Member of the BioNJ PM & Molecular Diagnostics Committee. He has been a frequently invited speaker on PM at conferences and to the leadership teams of many pharmaceutical companies, along with some notable business publications on this subject, including two (co) first authored papers in Nature Reviews, and such other journals as Supplement to Science and Personalized Medicine. As part of his extracurricular activities, he holds an Adjunct Professor position at the Chinese National Human Genome Center at Shanghai, Chinese Academy of Sciences, and Senior Advisor & Visiting Professor positions at the Beijing Genomics Institute.

Precision medicine, Personalized Medicine

John,Rutgers University, USA

Genetics

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With its solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 800 peer-reviewed publications. He is also Managing Partner of Salto Partners, a management consulting firm headquartered in the DC metro area. He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales and operations. Clients are operating in the high tech and life sciences space. Dr. Scherer holds a PhD in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! He is married and the proud father of one son.

Precision Medicine

Howard Moskowitz, Harvard PhD in experimental psychology (1969) is founding partner and chief scientific officer of Mind Genomics Advisors. He has published extensively in many fields, using the science of Mind Genomics, which he invented more than 30 years ago. After a distinguished dual career in science and business, he changed course, creating an institute to help younger professionals as well as students and business, benefit from the application of Mind Genomics to practical problems in society, including commerce, health, education, and socal issues. Along with hundreds of scientific papers, he has written/edited 27 published books, with an additional 15 books finished but not yet published. His ‘oeuvre’ of work using Mind Genomics is available for download to interested parties at https://www.dropbox.com/sh/vlyiqp6p5eom0m1/AAC1WRPuHOGpax6TLq-md824a?dl=0

Mind Genomics

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Dr. Sergey Zhuplatov is a Medical Director of the Metabolic Strategy and Development of AstraZeneca LP. Fort Washington, PA. He was graduated as MD at the Izhevsk State Medical Academy in Russia before finishing his fellowship in Internal Medicine/Endocrinology at Moscow Academy of Post diploma Education and Moscow Medical Institute of Transplantology in 1986. He accepted tenure and leading clinical consultant position in Endocrinology/Cardiology clinic at his Alma Mater ISMA. At this time, he started his Ph.D. dissertation in Cardiology with prevention of progressive CV events in Diabetes Mellitus Patients as the main topic, which was perfectly defended at Ural State Medical Academy on 1991. Dr. Zhuplatov has been working as an Assistant Professor and practicing physician till his emigration to the USA in 2002 as an exceptional ability person visa waiver. Before that he worked 2 years as a Medical Scientific Consultant for Merck S&D Co., and also as a Chief Medical Officer in Private Medical Clinic for 2 years. He published different works in Internal Medicine, Lipidology, Endocrinology, and Cardiology. He continued his scientific work in University of Utah Medical School till his merge to Pharmaceutical Industry in 2008. Since then he is working in Cardio/Metabolic area of Medical Affairs and Clinical Development of Bristol-Meyers Squibb and AstraZeneca Co. He currently resides in Bucks County PA with his wife Irina, Industrial Psychology Ph.D. They both like fine arts, travel, and reading. His two sons are graduate students in Economy and Medicine.

Diabetology,Lipids,Ischemic Heart Disease, Microcirculation,Echocardiography,Obesity.

Dr. Luigi Maselli received the Distinguished Doctor Award at San Raffaele University of Rome in honor of his significant contribution to Lifestyle Medicine in Italy. He is a neuroimmunologist with a PhD in Neurosciences and works as a Research Fellow at Sapienza University of Rome – School of Medicine and Dentistry and as a Visiting Fellow at Gabriele d’Annunzio University of Chieti-Pescara – School of Health Sciences. Dr. Maselli is the founding President of the Italian Lifestyle Medicine Association (ILMA). He is active in patient care, research, speaking, teaching and writing, and wrote the first Italian book on Lifestyle Medicine. After establishing his connection with the Institute of Lifestyle Medicine at Harvard Medical School, where he fell in love with Lifestyle Medicine, he established Lifestyle Medicine programs in several Italian universities. His overwhelming enthusiasm for life and propensity for helping others reflect the values that make Lifestyle Medicine unique- for the treatment and prevention of lifestyle-related chronic diseases.

Internal Medicine

Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, cell science, Trace elemts, biology, Biomedical Laboratory

Gillie Gabay is a systems science expert. Ms. Gabay is a systemic organizational consultant who leads changes that aim at creating an optimal fit between business strategies and organizational strategies. She studies health psychology, at the individual, group and system level researching behavioral processes in health, illness and healthcare. Ms. Gabay promotes a systemic integrated approach where multiple views are accounted for: The view of the health system, the view of the patient and the view of the clinician. She is a senior lecturer at the Organizational Consulting Graduate Program at the College of Management in Israel

Mind Genomics

Roukos DH, Ioannina University, Greece. Dimitrios Roukos, MD (Athens University, Greece), PhD (J.W.Goethe University, Frankfurt a.M., Germany), has moved his scientific interest after 25 years of reductionist medicine to network biology-based systems medicine. Assessing the clinical limitations of current traditional medicine to cure in the future incurable diseases such as cancer, has focused over the last 5 years on human cancer genome both structural variation and functional heterogeneity. His emerging goal is to understand how inherited and somatic mutations, epigenome, transcriptome and interactome abnormalities change chromatin dynamic states and gene expression. Emerging evidence suggests that this gene dysfunction and deregulation of cell signalling pathways drive tumorigenesis and metastasis. His ultimate goal is to approach next-generation anticancer drugs and biomarkers to future achievement of personalized medicine and network biology-based managment of cancer.Publication metrics: > 200 papers with ~ 5,000 citations (h=55) in PubMed, ISI, Scopus and current editor of two eBooks on personalized management of cancer and cancer genome heterogeneity-based treatment of cancer. Currently is key evaluator in European Commission (FP7 Systems Medicine area) and French National Research Agency (22 billion euros) participating in experts panel meeting in Brussels and Paris (end 2011) for the selection of best projects. He is leader of Translational Research in European Union Network of Excellence (EUNE) for gastric cancer and Personalized Cancer Genomic Medicine, Biobank in Ioannina University (Greece). He has been invited speaker and consensus member in multiple International Cancer Meetings. He serves as Editor-in-Chief, Associate Editor and Editorial board member in 20 influential journals.

Assessing limitations of conventional reductionist medicine, he have shifted to multi-scale genes, proteins, molecules, DNA, and RNA interactions in physical and functional networks. Revolutionary NGS technologies provide mow sequencing of DNA (whole genome, exome), transcriptome (RNA-seq, Chip-seq), epigenome (BS-seq) and also along with novel techniques (living cells imaging and computational models) also deeper insights into the grand challenge of interactome (multidimensional spatiotemporal protein-protein interactions). Integrating all these experimental data (omics, living-cells imaging, 3D-genome resolution and intra- and inter-cellular differentiation mapping) and large-scale clinical data into computational models, deep understanding of a personal genome code-lifestyle interactions network is beginning to be shaped. The perspectives of future medicine based on clinical genome and systems science are now rationally excellent for revolutionizing healthcare.

Anatoly Victorovich Skalny was born on the 12th of April, 1962 in Ivano-Frankovsk-City (Ukrain). Graduated school in Olyka village of Volynskaya oblast and medical faculty of Ivano-Frankovsk Medicine State Institute (1985) with honours. Began to carry aout scientific researches from 1979 in a student scientific society under the leadership of professor G.A. Babenko, a leading specialist in medicine elementology in Soviet Union. Ph.D. in Medicine (from 1990). Member of Council on trace elements in agriculture, biology and medicine in AS USSR and RAS (from 1987), Executive Committee of Moscow department of physicians-assistants' Society (from 1989), Boards in ecology and natural recources, science, culture and public health Political Consulting Council under the President of Russian Federation (from 1997), Member of advisory committee in ecology at Moscow City Parliament, co-founder of public movement "Healthy City - health of moscovites" (from 1998). In 1985–1991 worked as a research assistant, Junior Researcher and Researcher in department of restoration treatment of children with cerebral paralysis of Research Institute of common and justice psychiatry by V.P.Serbsky of HM USSR, department of alcoholism genetics in State Scientific Center of narcology of HM USSR. In 1988 he founded scientific-medical center "Element" that is the base to carry out researches of biosubstrates elemental content for medicine purposes during 11 years (for population, health and sanitary-hygienic organizations), scientific institutes such as Research Institute of pediatrics of RAMS, Center for perinatology, obstetrics and gynaecology of HM RF, Navy Institute of Hygiene of HM RF, colleges of medicine of Moscow, Ivanovo, Irkutsk, N.Novgorod and other cities. Center for Biotic Medicine, - autonomous non-profit organization (CBM), - was founded by A.V.Skalny in 1995 that is the unique scientific-methodical Center for problems of applied medicine elementology in RF and UIS. On the 19 of January, 2001 "Russian Society of Medicine Elementology" (RUSTEM) was founded to provide the strongest evolution of trace elements paradigm. During the period from 1982 about 200 scientific articles and thesis' were published by A.V.Skalny in special issues in Russia and abroad as well as manuals and mini-monographs in problems of practical medicine elementology. A.V. Skalny with co-authors registered 3 certificates of authorship and 3 patents of RF and Ukrain in the branch of producing new biologically active compounds of trace elements (Se, Zn) to treat and make prophylaxis of human diseases, methods of treatments of zinc deficiency states, alcohol coma and schysophrenia. To date new line in medicine and ecology, - medicine elementology, - is established by A.V. Skalny in Russia and UIS and developed successfully that studies peculiarities of human organism elemental composition in different functional states and disorders and the ways to increase organism adaptative functions with the help of trace elements metabolism correction. In SMC "Element" and CBM more than 20 Ph.D.'s and 5 D.Sc.' in medicine and biology were trained who develop different applied aspects of medicine elementology in branches of perinatology, endocrinology, urology, nephrology, labour medicine, nutrition hygiene, narcology in leaders clinics of Russia, Ukrain, Kazakhstan, Uzbekistan. In 1998-1999 production of new generation of effective major and trace elements' preparations (compounds with aspartic, spirulina) was organized under the methodic management of organizations headed by A.V. Skalny that awoke interest of specialists and consumers home and abroad. On April, 2003 A.V. Skalny opened the first chair of nutritiology and bioelementology in Russia and became its leader. From September, 2003 Bioelementology Institute, the first in the world, being founded by A.V. Skalny under support of Orenburg State University rectorate and RUSTEM, began its activity.

Internal Medicine (General Medicine)

Farid Menaa is an inter- and multi-disciplinar professional (director, professor, researcher and entrepreneur) with increasing international recognition. His strong background is mainly related to medecine, biology, pharmaceutical sciences, biochemistry, biophysics and genetics. Dr. Menaa has studied and worked for/with several reputed institutions worldwide, including Sorbonne (Paris, France), CNRS (France), INSERM (France), CEA (Ministry of Defence, France), SKCC/sanford-Burnham Medical Research Institute (USA), Schools of Medecine of Paris (France), Wuerzburg (Germany) and Campinas (Unicamp, Brazil). Among other responsibilities he carried out, Dr. Menaa has been, for several years, the R&D director of Fluorotronics, Inc. San Diego, CA, USA, a premier company specialized in fluorine chemistry and nanotechnology. Dr. Menaa was also a principal investigator in projects related to Oncology, Dermatology, Stem Cells, Genetics and Hematology. Dr. Menaa is currently an international consulting expert in healthcare and biosystems for a number of organizations and serves as an editorial board member for a large number of esteemed journals in medecine, sciences and business. Dr. Menaa holds dozen of peer-reviewed manuscripts and is a respected member of prestigious scientific/medical organizations and meetings where he is often invited as a chairman.

Medicine; Genetics; Fluorine Chemistry; Nanotechnology; Biophysics; Biochemistry

Deirdre Kelly Ph.D. career spans both industry and academia where she has worked with both start-up biotech and multinational pharmaceutical companies. Dr Kelly holds a PhD (Medicine, Immunology) from the Royal College of Surgeons in Ireland, a MSc Biotechnology from the National University of Ireland, Galway, and a B.A.(Mod) Biochemistry from Trinity College, Dublin. Dr Kelly founded Kelly Scientific which is a trusted premier provider of cutting edge niche market information within the pharma, biotech and healthcare industries. Personalized medicine, targeted therapeutics, companion diagnostics and immunotherapeutics are key areas that we have significant market expertize in. We are proud to count Fortune 500 companies as many of our repeat corporate clients. Kelly Scientific provides high quality comprehensive business reports for the Pharma/Biotech industry which are updated regularly. We have scientific and business expertise in a number of therapeutic and diagnostic areas including personalized medicine, transdermal and targeted drug delivery, immunotherapy, anti-infectives, respiratory and gastrointestinal disease, genetics, pharmacogenomics, vaccines, biomarkers, biosimilars, inflammation, oncology and diabetes. We are also constantly tracking the USA, European, Russian, Chinese, Indian, Japanese and African Pharma and Biotech markets.

Personalized medicine

Adrian Llerena is the Director of the Clinical Research Center in the University Hospital Infanta Cristina en Badajoz Spain. He is also Professor of Pharmacology and Clinical Pharmacology in two Medical Schools in the University of Extremadura Spain and part time in the University of Beira Interior, Portugal. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics of antidepressant and antipsychotic drugs. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 PhD thesis

Pharmacology, Personalized Medicine

Howard Moskowitz, Harvard PhD in experimental psychology (1969) is founding partner and chief scientific officer of Mind Genomics Advisors. He has published extensively in many fields, using the science of Mind Genomics, which he invented more than 30 years ago. After a distinguished dual career in science and business, he changed course, creating an institute to help younger professionals as well as students and business, benefit from the application of Mind Genomics to practical problems in society, including commerce, health, education, and socal issues. Along with hundreds of scientific papers, he has written/edited 27 published books, with an additional 15 books finished but not yet published. His ‘oeuvre’ of work using Mind Genomics is available for download to interested parties at https://www.dropbox.com/sh/vlyiqp6p5eom0m1/AAC1WRPuHOGpax6TLq-md824a?dl=0

Mind Genomics.

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, cell science, Trace elemts, biology, Biomedical Laboratory

Dr Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Ananda S. Prasad was born in Buxar, a small town in the state of Bihar, India. After graduation from high school, he joined Patna Science College, Patna University where he was top student in chemistry and received B.Sc degree with honors in mathematics. Prasad entered the Patna Medial College in Bihar, graduating there in 1951 with high distinction in physiology. In 1952 Prasad went to St. Paul’s Hospital, Dallas, Texas, for residency training in pathology, accompanied by his wife, who sought further training in obstetrics and gynecology. Contrary to the route taken by his classmates, Ananda Prasad decided not to seek Membership in the Royal College of Physicians (MRCP), England, and looked for additional training in the USA. He was accepted by Dr. C.J. Watson, a well known outstanding Professor of Medicine, for training in internal medicine at the University of Minnesota Medical School. He was trained at Minnesota to be a clinical scientist with research interests in calcium and magnesium metabolism. Thus began a lifelong interest in the metabolism of various elements, including zinc. Prasad then went to Iran at the invitation of Hobart A. Reimann, who had preceded Dr. Watson as Chief of Medicine in Minnesota, and was Chief of Medicine at the Nemazee Hospital of Pahlevi University in Shiraz, Iran. He was a personal friend of the Shah of Iran. Prasad left Iran in January 1961 and joined the department of Biochemistry and Medicine of Vanderbilt University under Dr. William J. Darby. Although Dr. Darby wanted Prasad to study porphyrin metabolism in Pellagra in Egypt, Prasad shared with Darby his speculation that zinc deficiency in the Middle East was prevalent and was responsible for widespread growth retardation. Darby approved plans to investigate zinc metabolism in growth-retarded subjects and Prasad was able to join the U.S. Naval Medical Research unit No.3 (NAMRU-3), in Egypt. Studies in Egypt showed that the growth retardation and gonadal hypofunction in these subjects were related to zinc deficiency. The anaemia was due to iron deficiency and responded to oral iron treatment. Ananda S. Prasad, M.D., Ph.D., has been at the WSU School of Medicine since 1963, when he took a position as director of the Division of Hematology. Dr. Prasad was appointed a Distinguished Professor of Medicine, Division of Hematology- Oncology, in 2000. Ananda Prasad has published over 300 papers and fifteen books. He was founding editor of two journals,American Journal of Hematology and Journal of Trace Elements in Experimental Medicine. Prasad has received much recognition for his contributions. These include AMA Goldberger Award, American College of Physicians Award for outstanding work in science as related to Medicine, Medal of Honor from Mayor of Lyon, France, First Raulin Award for pioneering research in zinc from International Society for Trace Elements Research in Humans (ISTERH), Robert H. Herman Award from American Society of Clinical Nutrition, Mastership from the American College of Physicians, inducted in the Heritage Hall of Fame, International Institute Foundation, Detroit, Michigan and Asian Academy Hall of Distinction Award, Washington, DC. Most importantly Prasad received the 2010 Prince Mahidol Award from Bangkok.

Medicine

María A. Pajares completed her PhD from the Universidad Complutense de Madrid (Spain) in 1986, and her postdoctoral studies from the Harvard Medical School (Boston, USA) in 1989. She is a Senior Research Scientist from the CSIC since 2006, where her own group works in the structure/function relationships that govern methionine metabolism in health and disease. She has authored more than 60 original papers in reputed international journals, she serves as referee for a large number of journals and several grant agencies and is now also serving as an Editorial Board member for the World Journal of Biological Chemistry.

Editorial Board member for the World Journal of Biological Chemistry.

Anatoly Victorovich Skalny was born on the 12th of April, 1962 in Ivano-Frankovsk-City (Ukrain). Graduated school in Olyka village of Volynskaya oblast and medical faculty of Ivano-Frankovsk Medicine State Institute (1985) with honours. Began to carry aout scientific researches from 1979 in a student scientific society under the leadership of professor G.A. Babenko, a leading specialist in medicine elementology in Soviet Union. Ph.D. in Medicine (from 1990). Member of Council on trace elements in agriculture, biology and medicine in AS USSR and RAS (from 1987), Executive Committee of Moscow department of physicians-assistants' Society (from 1989), Boards in ecology and natural recources, science, culture and public health Political Consulting Council under the President of Russian Federation (from 1997), Member of advisory committee in ecology at Moscow City Parliament, co-founder of public movement "Healthy City - health of moscovites" (from 1998). In 1985–1991 worked as a research assistant, Junior Researcher and Researcher in department of restoration treatment of children with cerebral paralysis of Research Institute of common and justice psychiatry by V.P.Serbsky of HM USSR, department of alcoholism genetics in State Scientific Center of narcology of HM USSR. In 1988 he founded scientific-medical center "Element" that is the base to carry out researches of biosubstrates elemental content for medicine purposes during 11 years (for population, health and sanitary-hygienic organizations), scientific institutes such as Research Institute of pediatrics of RAMS, Center for perinatology, obstetrics and gynaecology of HM RF, Navy Institute of Hygiene of HM RF, colleges of medicine of Moscow, Ivanovo, Irkutsk, N.Novgorod and other cities. Center for Biotic Medicine, - autonomous non-profit organization (CBM), - was founded by A.V.Skalny in 1995 that is the unique scientific-methodical Center for problems of applied medicine elementology in RF and UIS. On the 19 of January, 2001 "Russian Society of Medicine Elementology" (RUSTEM) was founded to provide the strongest evolution of trace elements paradigm. During the period from 1982 about 200 scientific articles and thesis' were published by A.V.Skalny in special issues in Russia and abroad as well as manuals and mini-monographs in problems of practical medicine elementology. A.V. Skalny with co-authors registered 3 certificates of authorship and 3 patents of RF and Ukrain in the branch of producing new biologically active compounds of trace elements (Se, Zn) to treat and make prophylaxis of human diseases, methods of treatments of zinc deficiency states, alcohol coma and schysophrenia. To date new line in medicine and ecology, - medicine elementology, - is established by A.V. Skalny in Russia and UIS and developed successfully that studies peculiarities of human organism elemental composition in different functional states and disorders and the ways to increase organism adaptative functions with the help of trace elements metabolism correction. In SMC "Element" and CBM more than 20 Ph.D.'s and 5 D.Sc.' in medicine and biology were trained who develop different applied aspects of medicine elementology in branches of perinatology, endocrinology, urology, nephrology, labour medicine, nutrition hygiene, narcology in leaders clinics of Russia, Ukrain, Kazakhstan, Uzbekistan. In 1998-1999 production of new generation of effective major and trace elements' preparations (compounds with aspartic, spirulina) was organized under the methodic management of organizations headed by A.V. Skalny that awoke interest of specialists and consumers home and abroad. On April, 2003 A.V. Skalny opened the first chair of nutritiology and bioelementology in Russia and became its leader. From September, 2003 Bioelementology Institute, the first in the world, being founded by A.V. Skalny under support of Orenburg State University rectorate and RUSTEM, began its activity.

Internal Medicine (General Medicine)

After medical studies at Aristotelian University in Greece, Constantin Polychronakos specialized in pediatric endocrinology in Canada and had post-doctoral research training at McGill University in Montreal, where he is now full professor in the Department of Paediatrics with cross-appointment in Human Genetics. He is credited with the discovery of the effect of the INS locus in the thymus in type 1 diabetes, with two of the first GWAS for type 1 and type 2 diabetes and one of the first uses of exon capture combined with NGS to elucidate the cause of a rare monogenic form of diabetes

.

Dr. Farid Menaa is an inter- and multi-disciplinar professional (director, professor, researcher and entrepreneur) with increasing international recognition. His strong background is mainly related to medecine, biology, pharmaceutical sciences, biochemistry, biophysics and genetics. Dr. Menaa has studied and worked for/with several reputed institutions worldwide, including Sorbonne (Paris, France), CNRS (France), INSERM (France), CEA (Ministry of Defence, France), SKCC/sanford-Burnham Medical Research Institute (USA), Schools of Medecine of Paris (France), Wuerzburg (Germany) and Campinas (Unicamp, Brazil). Among other responsibilities he carried out, Dr. Menaa has been, for several years, the R&D director of Fluorotronics, Inc. San Diego, CA, USA, a premier company specialized in fluorine chemistry and nanotechnology. Dr. Menaa was also a principal investigator in projects related to Oncology, Dermatology, Stem Cells, Genetics and Hematology. Dr. Menaa is currently an international consulting expert in healthcare and biosystems for a number of organizations and serves as an editorial board member for a large number of esteemed journals in medecine, sciences and business. Dr. Menaa holds dozen of peer-reviewed manuscripts and is a respected member of prestigious scientific/medical organizations and meetings where he is often invited as a chairman.

Medicine; Genetics; Fluorine Chemistry; Nanotechnology; Biophysics; Biochemistry

Adrián LLerena is the Director of the Clinical Research Center in the University Hospital Infanta Cristina en Badajoz Spain. He is also Professor of Pharmacology and Clinical Pharmacology in two Medical Schools in the University of Extremadura Spain and part time in the University of Beira Interior, Portugal. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics of antidepressant and antipsychotic drugs. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 PhD thesis

pharmacology, personalized medicine

Andreas Scherer is the Project Director for Institute for Molecular Medicine Finland (FIMM)and previously he was a founder and CEO of Spheromics, a company focused on consultancy in biomarker development, as well as analysis and interpretation of complex biomedical datasets. Dr Scherer is a molecular and computational biologist with long experience in gene expression profiling and biomarker development and qualification. Before founding Spheromics in 2007, Dr Scherer worked in various positions for Novartis in Basel, Switzerland. In 2011 he accepted the position Bioinformatics Manager at the Australian Genome Research Facility (AGRF) in Melbourne, AU, from where he returned to Finland in 2013. Dr Scherer is author and co-author of a number of articles in peer-reviewed journals, book chapters, and editor of a book about unwanted variation in microarray datasets. He is advisory board member of the journal “OA Bioinformatics”.

Bioethics, Genomics, Biomarkers

Dr. Stephen Wang received his training in pharmaceutical sciences at the Texas Medical Center under Professor Ming Hu. Dr. Wang currently serves as a senior principal scientist in the Pharmacokinetics, Dynamics and Metabolism Division of Pfizer in Cambridge, MA. Previously, Dr. Wang served as a biotransformation group leader responsible for enzymology drug-drug interactions for Millennium Takeda Pharmaceuticals in Cambridge MA. In addition to this, Dr. Wang also served as a senior scientist in the department of Drug Metabolism and Pharmacokinetics at Schering Plough Research Institute which was later acquired by Merck. Dr. Wang’s research interests focus on mechanistic PK/PD modeling for both small and large molecules as well as physiologically based pharmacokinetic modeling for the assessment of drug drug interaction potential. Dr. Wang has made significant contributions in the field with a consistent publication track record of manuscripts in peer-reviewed scientific journals and various book chapters.

.

Dr. Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

.

Luiza Spiru, MD, PhD is Professor of Geriatrics and Gerontology at Carol Davila” University of Medicine and Pharmacy and beginning with 1999, the Head of the Geriatric and Geronto-Psychiatry University Department, to Ana Aslan National Institute of Geriatrics Gerontology (1999-2003) and “Elias” University Emergency Hospital in Bucharest (2003 – in present). After doctorate (1997) she acquired multiple specializations in Molecular Medicine, Geriatrics Gerontology and Old Age Psychiatry and therewith several competences in: Cell Biology, Neuro-PsychoPharmacology, Abdominal and Heart Ultrasound-Investigations, IT in medical services, Standardized Geriatric Evaluation, Diagnosis and Treatment of Memory Impairment Diseases, Differential Diagnosis of Alzheimer Dementia’s and other related Dementia, Health Services Management, MBA - British Council, Leadership Management International - Effective Personal Productivity, Texas USA.

Mukesh Verma is a Program Director and Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genetics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Before coming to the DCCPS, he was a Program Director in the Division of Cancer Prevention (DCP), NCI, providing direction in the areas of biomarkers, early detection, risk assessment and prevention of cancer, and cancers associated with infectious agents. He holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 136 research articles and reviews and edited three books in cancer epigenetics and epidemiology field.

Biomarkers, Cancer epigenetics , Epidemology,

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Biomedical Laboratory

Dr. Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Internal medicine, Allergy, Immunology, Pharmaceutical analysis,Biomarkers

Gérard Siest, PhD, will receive the 46th annual award, sponsored by Bayer Diagnostics. He offers the following biographical sketch: He finished his Pharmacy studies in Strasbourg and Nancy, specialized in Laboratory Medicine. After a hospital residency (2 years) he passed the certificates of Clinical Biochemistry, of Microbiology, of Hematology, and of Bacteriology. He received a PhD in Biochemistry in 1966. Having obtained these skills in clinical biology, he applied them progressively to creation of the Centre for Screening of Metabolic Diseases at the Hospital of Nancy and then to creation of the Laboratory of the Centre for Preventive Medicine. During this time, he developed his university career, successively being Assistant then Associate Professor, finally Professor of Clinical Biochemistry, and then of Molecular Biology and of Molecular Pharmacology. He accepted in succession several responsibilities: Dean of the Faculty of Pharmaceutical Sciences, Chairman of the Scientific Council of the Faculty, and Vice-President of the University. On a regional scale, He look after many research structures and serve on a national scale as a member of CNRS and INSERM commissions. He is presently the President of the Research Committee on Cholesterol and Lipids (ARCOL). Twelve Professors or Research Directors have been selected from our team. Since 1970, he have organized nine Colloquiums of Prospective Biology at Pont-à-Mousson every 3 or 4 years, in addition to numerous other scientific meetings. He was also a member of the International Federation of Clinical Chemistry (IFCC) Expert Panel on Reference Values and Chairman of the Expert Panel on Drug Effects. Finally, in my recent activities, he assumed the Presidency of the IFCC for 6 years, developing a strategic plan and promoting the evolution of this organization, which increased from 50 members to 73 under my presidency. They also developed a public relations action and many contacts with other international sister organizations and signed new agreements with two regions (South America and Europe). He is currently the head of the Centre du Médicament and I run the Laboratory and the Research of the Centre for Preventive Medicine. His research activities are oriented, on the one hand, towards the study of reference values and the knowledge of biological variations in laboratory examinations, including those due to drugs. This is furthered by the Centre for Preventive Medicine, which examines each year 70 000 subjects supposed to be in good health. On the other hand, he is in charge of a research team in the cardiovascular risks domain linked to lipoprotein metabolism. We particularly wish to understand better the functions, the clinical interest, and the pharmacological target of the apolipoproteins. Apolipoprotein E is of special interest, being at relatively high concentrations in tissue damaged through oxidation. More than 500 original publications and more than 20 books carry his name. he is a member of many scientific societies and of the editorial boards of clinical chemistry and pharmacology journals. He is now Editor, European Journal of Clinical Chemistry and Clinical Biochemistry.

Pharmacology, Personalized Medicine

Edward D Blair PhD MBA is a molecular biochemist with 15 years experience in the pharmaceutical industry, recently as a Director ofApplied Diagnostics & Surrogates at GlaxoSmithKline and is a visiting scholar at the University of Cambridge. He has been directly involved in pharma R&D from target identification to clinical trials, notably withAmprenavir (HIV) and Relenza (influenza). He has developed programmes that support the strategic integration of surrogate biomarkers & diagnostics into the drug development pipe-line from candidate selection to approval & launch. His broad therapeutic area experience includes viral, respiratory, liver and neurodegenerative disease, frequently in collaboration with esteemed academic groups. He is an expert in the field of virology having edited two books and co-authored over thirty papers & five patents

Pharma, Biomarkers and Molecular Diagnostics

Dr Farid MENAA has completed his Ph.D in radiation oncology and gerontology from the French Atomic Energy Authority (CEA- 2003) and University of Paris (Jussieu-Sorbonne). Thereafter, he completed three international post-doctoral terms in medicine, genomics, sciences and technology. Among other professional activities, he is currently the R&D executive director of Fluorotronics Inc., a chemical and nanotechnology company. He has published many papers in reputed journals and serving as an editorial board member of prestigious scientific journals. His main current focuses are related to preventive, personalized, translational, integrative and regenerative medicine, in order to prevent and implement early diagnosis and efficient therapy.

Oncology, Gerontology, Genetics, Biochemistry, Pharmacy and Nanomedicine

Allen D. Roses has established an international reputation for his work in pharmacogenetics, exploratory drug discovery, and clinical neuroscience.Dr. Roses also serves in several capacities at Duke University: as Jefferson-Pilot Professor of Neurobiology and Genetics, as Director of the Deane Drug Discovery Institute, and as Senior Scholar at the Fuqua School of Business.Dr. Roses was a member of the Science Board of the US Food and Drug Administration between 2003-2007. He recently returned to Duke after a decade-long career as a Senior Vice President at GlaxoSmithKline (GSK) and its corporate predecessor GlaxoWellcome (GW),Founding Director of the Joseph and Kathleen Bryan Alzheimer\'s Disease Research Center, Chief of the Division of Neurology, and Director of the Center for Human Genetics.

Pharmacogenetics and Neuroscience

Dr. Xiaohua Douglas Zhang is an Associate Director, Scientific Staff, in Merck Research Laboratories. He got his Ph.D. in statistics from Carnegie-Mellon University, PA, USA, an MS in Genetics and a BS in Biology from Beijing Normal University, China. He has worked on analyzing data generated from new biotechnologies. He has analyzed many high-throughput screening (HTS) projects for many years. Merck has put great effort into RNAi research. It purchased Sirna for $1.1 billion in 2006 and has one of the largest labs for conducting RNAi/compound HTS. Since early 2005, Dr. Zhang has led data analysis in RNAi HTS projects at Merck and has continuously developed and adopted experimental designs and analytic methods for HTS projects including novel analytic methods for quality controls and hit selection, which allows him and his colleagues to continuously publish papers in the HTS area. He has a book titled "Optimal High-Throughput Screening: Practical Experimental Design and Data Analysis for Genome-scale RNAi Research" published by Cambridge University Press in 2011. He has organized/chaired many sessions in professional meetings, has reviewed grant proposals for NIH and European Commission, and has refereed many manuscripts submitted to prestigious journals such as Nature, Nature Methods, Journal of American Statistical Association, Bioinformatics, etc.

Bioinformatics

Dr Andreas Scherer is the founder and CEO of Spheromics, a company focused on consultancy in biomarker development, as well as analysis and interpretation of complex biomedical datasets. Dr Scherer is a molecular and computational biologist with long experience in gene expression profiling and biomarker development and qualification. Before founding Spheromics in 2007, Dr Scherer worked in various positions for Novartis in Basel, Switzerland. In 2011 he accepted the position Bioinformatics Manager at the Australian Genome Research Facility (AGRF) in Melbourne, AU, from where he returned to Finland in 2013. Dr Scherer is author and co-author of a number of articles in peer-reviewed journals, book chapters, and editor of a book about unwanted variation in microarray datasets. He is advisory board member of the journal “OA Bioinformatics”.

Bioethics, Genomics, Biomarkers

Anil Modak is the Associate Director of Medical Products Research Development at Cambridge Isotope Laboratories in Andover. Dr. Anil Modak has been involved in the design research and development of novel non invasive breath tests for personalized medicine using stable isotope substrates for the diagnosis of disease states and evaluation of enzyme activity. He is the author of several recent patents and publications. He had reviewed papers for reputed journals and authored one book chapter. He serves on the Editorial board of the Journal of Breath Research. His previous experience includes working for Ribozyme Pharmaceuticals in Boulder CO and Monsanto in St. Louis, MO. His postdoctoral research was conducted at the University of Iowa and Kings College London.

Design and develop novel, non invasive, phenotype breath tests using stable isotope substrates for identifying non responders for various drugs metabolized by specific P450 CYP enzymes to enable physicians to personalize medication.

Dik C. van Gent did his PhD at the Netherlands Cancer Institute (NKI) and postdoctoral studies at the National Institutes of Health (USA). He is now Associate Professor at the world-renowned DNA repair group at the Department of Genetics of the Erasmus MC Rotterdam, one of the largest university medical centers in The Netherlands. He has published more than 50 papers in reputed journals, including Cell, Science and Nature and serves as an editorial board member of ‘DNA Repair’ and ‘Genome Integrity’

‘ex vivo’ and study the DDR by inducing DNA damage in cultured tumor cells

Dr. Sholler received her M.S. in Microbiology and Immunology from McGill University and her M.D. from New York Medical College. At Brown University, she performed a residency in pediatrics and a fellowship in pediatric oncology/hematology. Prior to joining VAI, Dr. Sholler most recently worked in the Division of Pediatric Hematology/Oncology at the University of Vermont. Dr. Sholler joined VAI in 2011 as Co-Director of the Pediatric Oncology Program, Associate Professor in the Center for Cancer Genomics and Quantitative Biology, and Head of the Laboratory of Neuroblastoma Translational Research. She is jointly appointed with the Helen DeVos Children\'s Hospital as the Haworth Family Director of the Innovative Therapeutics Clinic in the Division of Pediatric Oncology. As well, she is Chair of the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) and Guest Researcher within the Pediatric Oncology Branch at NCI/NIH.

Liang Cheng, MD was chosen President of the International Association of Chinese Pathologists for 2006-2007. Dr. Cheng is an Associate Professor of pathology and urology and Director of the Clarian Molecular Pathology Laboratory. Dr. Cheng is also the 2006 award winner of the Arthur Purdy Stout Annual Prize which recognizes significant career achievements by a surgical pathologist under the age of 45 whose research publications have had a major impact on diagnostic pathology. The prize was created in memory of Dr. Arthur Purdy Stout who was one of the pioneers of oncological surgical pathology.

Molecular Genetic Pathology

Dr Sankar M.D., M.P.H a physician trained in India and the University of West Indies as an internist who also possess a master of public health degree from Queensland Australia. He has have over 12 years of experience working in the life sciences industry with biotech/Pharma companies and governmental organizations like NCI and NHLBI providing clinical development and operations support in the analysis of clinical and safety data for drugs and biologics. His depth of experience also spans across other areas in clinical development including Quality assurance and clinical trial monitoring. Dr Sankar is an expert on ICH/GCP regulations and is a certified clinical research professional with SOCRA. He is an active member of SOCRA, DIA, ASCO, EPPIC Global, Tie Silicon valley and ACRP. Dr Sankar’s therapeutic area expertise includes immunology, oncology, hematology, infectious diseases and CNS. He has been involved as part of the NDA submission for 2 compounds one each for oncology and CNS. Dr Sankar also serve on the various sub committees within DIA focused on clinical development, clinical trial design, quality risk management and good clinical practices.

Immunology and Molecular Diagnostics

Adrián LLerena is the Director of the Clinical Research Center in the University Hospital Infanta Cristina en Badajoz Spain. He is also Professor of Pharmacology and Clinical Pharmacology in two Medical Schools in the University of Extremadura Spain and part time in the University of Beira Interior, Portugal. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics of antidepressant and antipsychotic drugs. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 PhD thesis

pharmacology